VBL Therapeutics Release: Keystone Symposium Highlights Positive Preclinical Data on Novel Immune Modulator

TEL AVIV, Israel & KYOTO, Japan--(BUSINESS WIRE)--VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced preclinical data demonstrating that VB-201 regulates inflammatory pathways, suggesting that it may effectively control inflammatory responses associated with autoimmune diseases and atherosclerosis. These results were presented today at the Keystone Symposium on Bioactive Lipids: Biochemistry and Diseases in Kyoto, Japan by Eyal Breitbart, Ph.D., vice president of research at VBL.